CD3/CD19 bispecific BiTE (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 mu g/m(2)and day by Continuous Infusion is Tolerable and Results in Durable Responses

MLA

Knop, S., et al. CD3/CD19 Bispecific BiTE (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 Mu g/m(2)and Day by Continuous Infusion Is Tolerable and Results in Durable Responses. Jan. 2010. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.unidue...bib..22910060369e8b397249866e019cc824&authtype=sso&custid=ns315887.

APA

Knop, S., Goebeler, M., Viardot, A., Noppeney, R., Topp, M. S., Nagorsen, D., Scheele, J. S., Libicher, M., Zugmaier, G., Klinger, M., Schmidt, M., Klappers, P., Kufer, P., Einsele, H., & Bargou, R. C. (2010). CD3/CD19 bispecific BiTE (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 mu g/m(2)and day by Continuous Infusion is Tolerable and Results in Durable Responses.

Chicago

Knop, S., M. Goebeler, A. Viardot, Richard Noppeney, M. S. Topp, D. Nagorsen, J. S. Scheele, et al. 2010. “CD3/CD19 Bispecific BiTE (R) Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients : 60 Mu g/m(2)and Day by Continuous Infusion Is Tolerable and Results in Durable Responses,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.unidue...bib..22910060369e8b397249866e019cc824&authtype=sso&custid=ns315887.